Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Raymond Moses: Unleashing the Financial Potential of Billions!
Unichem Laboratories is currently trading at Rs. 237.20, up by 6.20 points or 2.68% from its previous closing of Rs. 231.00 on the BSE.
The scrip opened at Rs. 229.00 and has touched a high and low of Rs. 241.40 and Rs. 229.00 respectively. So far 8881 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 334.00 on 06-Oct-2015 and a 52 week low of Rs. 174.00 on 08-Jun-2015.
Last one week high and low of the scrip stood at Rs. 241.40 and Rs. 214.70 respectively. The current market cap of the company is Rs. 2139.76 crore.
The promoters holding in the company stood at 50.11% while Institutions and Non-Institutions held 18.57% and 31.32% respectively.
Unichem Laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Quetiapine Fumarate Tablets. Quetiapine Fumarate Tablets 25mg, 50mg, 100mg, 200mg, 300mg and 400mg are therapeutically equivalent to Seroquel Tablets, 25mg, 50mg, 100mg, 200mg, 300mg and 400mg of AstraZeneca Pharmaceuticals LP.
Quetiapine Fumarate is an atypical antipsychotic indicated for the treatment of Schizophrenia. Quetiapine Fumarate is also indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex and for maintenance treatment as an adjunct to lithium or divalproex. It is also indicated as a monotherapy for the acute treatment of depressive episodes associated with bipolar disorder.
The product will be commercialized from the company’s Ghaziabad plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur API Plant. The company has now has total of 21 ANDA approvals from USFDA.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1863.60 |
| Dr. Reddys Lab | 6552.50 |
| Cipla | 1639.50 |
| Lupin | 2152.15 |
| Zydus Lifesciences | 1055.40 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
